Hims & Hers Stock Unravels Toward $45 as Pricing Fears and CEO Sale Hit Hard
Hims & Hers Health (NASDAQ: HIMS) saw its strong midweek rally collapse into a steep selloff as renewed pricing concerns and insider selling
Quick overview
- Hims & Hers Health experienced a 23% stock decline after reaching over $65, driven by concerns over pricing policies for weight-loss medications.
- Insider selling by CEO Andrew Dudum, who sold $11 million worth of shares, heightened investor unease about the company's future.
- Despite reaffirming its revenue forecast for 2025, the company faces challenges from market volatility and potential pricing pressures on its growth prospects.
- Investor sentiment has soured, with the stock needing to hold above $50 to avoid further declines toward the $45 support level.
Hims & Hers Health (NASDAQ: HIMS) saw its strong midweek rally collapse into a steep selloff as renewed pricing concerns and insider selling reignited investor caution.
Rally Turns Sour After Policy Remarks
After soaring above $65 on Wednesday following its menopause and perimenopause service launch, Hims & Hers stock plunged 23% over the next two sessions, sliding toward the critical $50 support level. The reversal followed remarks from U.S. President Trump, who vowed to bring down the cost of popular weight-loss medications — a key revenue driver for Hims’ telehealth business.
During Thursday’s press conference, Trump referred to Ozempic as “the fat loss drug,” promising that prices would be “much lower” in the near future. Although no clear timeline was given, the comments rattled investors, raising concerns that price controls or negotiations could severely erode profit margins for companies reliant on branded or compounded weight-loss treatments.
HIMS Chart Daily – Returning Lower After Failing to Make A New High
If the stock fails to hold the $50 threshold, analysts warn that the next technical support rests near $45, at the 200-day simple moving average — a level that previously helped stabilize the stock during its April lows.
Insider Selling Deepens Investor Unease
The decline intensified on Friday after regulatory filings revealed that CEO Andrew Dudum sold 175,661 shares of Hims & Hers stock, valued at roughly $11 million. The sale, disclosed in a U.S. Securities and Exchange Commission (SEC) filing, took place immediately after the stock’s midweek rebound — adding to concerns about management’s confidence in the company’s near-term trajectory.
While insider sales don’t always signal trouble, the timing—coming just as shares were regaining momentum—sparked renewed doubts among traders already spooked by external policy risk.
Growth Prospects Tested by Market Volatility
Earlier in 2025, Hims & Hers had been one of the year’s standout performers, surging above $73 in February amid investor enthusiasm for digital health and telemedicine platforms. That optimism, however, faded as growth stocks fell out of favor and broader market volatility picked up.
The company’s strategic partnership with Novo Nordisk (NYSE: NVO)—enabling telehealth access to the blockbuster Wegovy treatment—had been viewed as a key growth driver. But the latest political push for lower drug prices may challenge the profitability of such collaborations, particularly if consumer expectations for cheaper access outpace the company’s pricing flexibility.
Financial Outlook Remains Cautiously Optimistic
Despite market turbulence, Hims & Hers reaffirmed its 2025 revenue forecast of $2.3–$2.4 billion, aligning with consensus estimates. For the current quarter, management projects revenue between $570 million and $590 million, with adjusted EBITDA in the $60–$70 million range.
While Q2 earnings missed expectations, executives reiterated their confidence in long-term growth—especially in niche, high-margin areas like mental health and hormone therapy.
Conclusion: Confidence Shaken
The recent plunge underscores growing investor unease around policy risks, insider actions, and valuation sustainability in the telehealth sector. Though Hims & Hers remains a major player with a strong product portfolio, sentiment has clearly soured.
Unless the stock finds firm footing around $50, further declines toward $45 remain possible — a sobering reminder that even high-growth names can’t escape the weight of political and market pressures.
- Check out our free forex signals
- Follow the top economic events on FX Leaders economic calendar
- Trade better, discover more Forex Trading Strategies
- Open a FREE Trading Account
Save